In patients with osteoporosis, should subclinical hyperthyroidism be treated?
In patients with osteoporosis, should subclinical hyperthyroidism be treated? Evidence-based answer: Subclinical hyperthyroidism with thyroid-secreting hormone (TSH) [less than or equal to] 0.45 mIU/L is associated with an increased fracture rate (SOR: A, meta-analysis of cohort studies), but treatment of subclinical hyperthyroidism when TSH is [less than or equal to] 0.2 mIU/L only slightly increases bone mineral density (BMD) (SOR: C, case-control study with disease-oriented outcomes). Current guidelines recommend clinicians "strongly consider" treatment of subclinical hyperthyroidism in patients with osteoporosis and TSH persistently [less than] 0.1 mIU/L (SOR: C,expert opinion).
Evidence-based practice 20, no. 4 (2017): 03